Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Given Average Recommendation of “Moderate Buy” by Analysts

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) has been assigned an average rating of “Moderate Buy” from the nine brokerages that are presently covering the company, Marketbeat.com reports. Four analysts have rated the stock with a hold recommendation, four have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $8.83.

MRNS has been the topic of several research analyst reports. EF Hutton Acquisition Co. I upgraded Marinus Pharmaceuticals to a “strong-buy” rating in a report on Monday, September 30th. Oppenheimer upgraded Marinus Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 price objective on the stock in a report on Monday, September 23rd. JMP Securities reiterated a “market perform” rating on shares of Marinus Pharmaceuticals in a report on Thursday. Cantor Fitzgerald reiterated an “overweight” rating and issued a $13.00 price objective on shares of Marinus Pharmaceuticals in a report on Tuesday, September 24th. Finally, LADENBURG THALM/SH SH cut Marinus Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Wednesday, August 14th.

Marinus Pharmaceuticals Stock Down 82.5 %

Shares of Marinus Pharmaceuticals stock opened at $0.30 on Friday. Marinus Pharmaceuticals has a twelve month low of $0.28 and a twelve month high of $11.26. The business has a 50-day moving average price of $1.57 and a 200 day moving average price of $1.67. The firm has a market cap of $16.26 million, a PE ratio of -0.11 and a beta of 1.14.

Marinus Pharmaceuticals (NASDAQ:MRNS) last announced its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.01). Marinus Pharmaceuticals had a negative net margin of 493.14% and a negative return on equity of 7,831.35%. The business had revenue of $8.06 million during the quarter, compared to analysts’ expectations of $9.05 million. During the same quarter in the prior year, the firm earned ($0.61) EPS. On average, sell-side analysts expect that Marinus Pharmaceuticals will post -1.93 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in MRNS. Avoro Capital Advisors LLC raised its position in shares of Marinus Pharmaceuticals by 31.4% during the 1st quarter. Avoro Capital Advisors LLC now owns 4,140,607 shares of the biopharmaceutical company’s stock valued at $37,431,000 after buying an additional 990,607 shares during the period. Vanguard Group Inc. raised its position in shares of Marinus Pharmaceuticals by 5.0% during the 1st quarter. Vanguard Group Inc. now owns 2,805,920 shares of the biopharmaceutical company’s stock valued at $25,366,000 after buying an additional 132,689 shares during the period. Acadian Asset Management LLC purchased a new stake in shares of Marinus Pharmaceuticals during the 2nd quarter valued at approximately $813,000. Renaissance Technologies LLC purchased a new stake in shares of Marinus Pharmaceuticals during the 2nd quarter valued at approximately $727,000. Finally, Assenagon Asset Management S.A. raised its position in shares of Marinus Pharmaceuticals by 70.3% during the 3rd quarter. Assenagon Asset Management S.A. now owns 444,185 shares of the biopharmaceutical company’s stock valued at $782,000 after buying an additional 183,396 shares during the period. 98.80% of the stock is currently owned by institutional investors and hedge funds.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.